脑胶质瘤组织ZEB2、CCL20表达及其与患者预后的相关性

doi:10.3969/j.issn.1006-5725.2024.09.014

Abstract

Abstract:

Objective To investigate the expression of zinc finger E-box-binding protein 2（ZEB2） and CC chemokine ligand 20 （CCL20） in glioma tissue and their relationship with prognosis. Methods The tumor tissues of 156 patients with glioma were collected as tumor group and 52 normal brain tissues of the same period were collected as normal group. The expression of ZEB2 and CCL20 in tissues were detected by immunohistochemistry， and the relationship between the expression and survival was analyzed by Kaplan-Meier survival curve. Patients in the tumor group were followed up for three years and grouped into a poor prognosis group and a good prognosis group based on their survival status， and the prognostic factors were analyzed by COX regression. Results The positive expression rate of ZEB2 and CCL20 in the tumor group were higher than those in the normal group （P < 0.05）. The 3-year survival rate of 156 glioma patients was 69.87%. The survival rate of patients with positive ZEB2 and CCL20 expression was lower than that of patients with negative expression （P < 0.001）. Age， maximum tumor diameter， tumor pathological grade， and positive expression of ZEB2 and CCL20 were all risk factors for poor prognosis of patients with glioma （P < 0.05）， and preoperative KPS， postoperative radiotherapy， and course of temozolomide treatment were all protective factors （P < 0.05）. Conclusion The expression level of ZEB2 and CCL20 in tumor tissues of glioma patients is up-regulated， and related to the prognosis of patients.

Key words: glioma, zinc finger E-box-binding protein 2, CC chemokine ligand 20, prognosis

CLC Number:

R739.4

Shihe XIAO,Gang LI,Zhonghai LIU,Zhen. LIU. Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis[J]. The Journal of Practical Medicine, 2024, 40(9): 1262-1267.

Figures/Tables 6

Tab.1

Fig.1

Fig.2

Tab.2

Tab.3

Tab.4

References 25

1	WANG J， TANG W， YANG M， et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy ［J］. Biomaterials， 2021， 273（1）：120784-120797. doi:10.1016/j.biomaterials.2021.120784 doi: 10.1016/j.biomaterials.2021.120784
2	穆素会. 贝伐单抗联合替莫唑胺治疗脑胶质瘤的临床研究［J］.实用癌症杂志， 2022， 37（4）：683-686. doi:10.3969/j.issn.1001-5930.2022.04.043 doi: 10.3969/j.issn.1001-5930.2022.04.043
3	QIU Z， YU Z， XU T， et al. Novel nano-drug delivery system for brain tumor treatment ［J］. Cells， 2022， 11（23）：3761-3778. doi:10.3390/cells11233761 doi: 10.3390/cells11233761
4	陈思思，邓钢. 脑胶质瘤CHSY1的表达变化及临床意义的生信分析［J］. 中国临床神经外科杂志， 2021， 26（8）：607-611.
5	苏纯，李巧云，张燕. miR-200在子宫内膜癌组织中的表达及与ZEBZ蛋白的相关性［J］. 实用医学杂志，2016，32（18）：3057-3059.
6	MYUNG J K， CHOI S AH， KIM S K， et al. The role of ZEB2 expression in pediatric and adult glioblastomas ［J］. Anticancer Res， 2021， 41（1）：175-185. doi:10.21873/anticanres.14763 doi: 10.21873/anticanres.14763
7	刘欣欣，姚欣卉，孙跃峰，等. 乳腺癌微环境中趋化因子CCL20作用的研究进展［J］. 实用肿瘤学杂志， 2022， 36（3）：250-254.
8	SCHULZ H， DIETRICHS D， WEHLAND M， et al. In prostate cancer cells cytokines are early responders to gravitational changes occurring in parabolic flights ［J］. Int J Mol Sci， 2022， 23（14）：7876-7889. doi:10.3390/ijms23147876 doi: 10.3390/ijms23147876
9	闫真. ZEB2和TGF-β1在上皮性卵巢癌组织中表达的相关性及预后意义［D］. 洛阳：河南科技大学， 2016.
10	杨通衢，韩志桐，赵卫平，等. 微流控芯技术检测循环肿瘤细胞在脑胶质瘤预后预测中的价值［J］. 中国癌症杂志， 2021， 31（10）：905-911.
11	韦继明，仇洪，张传东，等. 术中超声辅助显微切除术治疗脑胶质瘤的临床效果分析［J］. 海军医学杂志， 2022， 43（5）：527-530. doi:10.3969/j.issn.1009-0754.2022.05.019 doi: 10.3969/j.issn.1009-0754.2022.05.019
12	POONAN P， AGONI C， IBRAHIM M A A， et al. Glioma-targeted therapeutics： computer-aided drug design prospective ［J］. Protein J， 2021， 40（5）：601-655. doi:10.1007/s10930-021-10021-w doi: 10.1007/s10930-021-10021-w
13	李德培，陈忠平. 脑胶质瘤治疗现状与进展［J］. 实用医学杂志，2021，37（18）：2312-2316. doi:10.3969/j.issn.1006-5725.2021.18.002 doi: 10.3969/j.issn.1006-5725.2021.18.002
14	董星艺，韩贵娟，王明华. 99Tcm标记的经聚乙二醇修饰的黑色素纳米颗粒的制备及脑胶质瘤的初步显像研究［J］. 实用医学杂志，2020，36（13）：1733-1738. doi:10.3969/j.issn.1006-5725.2020.13.009 doi: 10.3969/j.issn.1006-5725.2020.13.009
15	FARDI M， ALIVAND M， BARADARAN B， et al. The crucial role of ZEB2： From development to epithelial-to-mesenchymal transition and cancer complexity ［J］. J Cell Physiol， 2019， 234（9）：14783-14799. doi:10.1002/jcp.28277 doi: 10.1002/jcp.28277
16	LEE M， LIM S， KIM Y S， et al. DEP-induced ZEB2 promotes nasal polyp formation via epithelial-to-mesenchymal transition ［J］. J Allergy Clin Immunol， 2022， 149（1）：340-357. doi:10.1016/j.jaci.2021.04.024 doi: 10.1016/j.jaci.2021.04.024
17	XIE H， WU Z， LI Z， et al. Significance of ZEB2 in the immune microenvironment of colon cancer ［J］. Front Genet， 2022， 13（1）：995333-995346. doi:10.3389/fgene.2022.995333 doi: 10.3389/fgene.2022.995333
18	WANG K， YANG S， GAO Y， et al. MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β-catenin signaling pathway ［J］. Oncol Lett， 2020， 19（1）：992-1000.
19	CHENG H， ZHAO H， XIAO X， et al. Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124 ［J］. Mol Neurobiol， 2021， 58（3）：1006-1016. doi:10.1007/s12035-020-02165-0 doi: 10.1007/s12035-020-02165-0
20	NAGAISHI M， FUJII Y， SUGIURA Y， et al. Increased Twist and ZEB2 expression in a cutaneous metastasis of high-grade glioma ［J］. Neuropathology， 2020， 40（2）：196-201. doi:10.1111/neup.12621 doi: 10.1111/neup.12621
21	KADOMOTO S， IZUMI K， MIZOKAMI A. The CCL20-CCR6 axis in Cancer progression ［J］. Int J Mol Sci， 2020， 21（15）：5186-5199. doi:10.3390/ijms21155186 doi: 10.3390/ijms21155186
22	CHEN Z， CHEN G， ZHAO H. FDPS promotes glioma growth and macrophage recruitment by regulating CCL20 via Wnt/β-catenin signalling pathway ［J］. J Cell Mol Med， 2020， 24（16）：9055-9066. doi:10.1111/jcmm.15542 doi: 10.1111/jcmm.15542
23	FAN T， LI S， XIAO C， et al. CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition ［J］. Int J Biol Sci， 2022， 18（11）：4275-4288. doi:10.7150/ijbs.73275 doi: 10.7150/ijbs.73275
24	NAN H， ZHOU L， LIANG W， et al. Epigenetically associated CCL20 upregulation correlates with esophageal cancer progression and immune disorder ［J］. Pathol Res Pract， 2021， 228（1）：153683-153697. doi:10.1016/j.prp.2021.153683 doi: 10.1016/j.prp.2021.153683
25	MO M， TONG S， HUANG W， et al. High serum CCL20 is associated with tumor progression in penile cancer ［J］. J Cancer， 2020， 11（23）：6812-6822. doi:10.7150/jca.48939 doi: 10.7150/jca.48939

组别	例数	ZEB2		CCL20
组别	例数	阳性	阴性	阳性	阴性
肿瘤组	156	106（67.95）	50（32.05）	98（62.82）	58（37.18）
正常组	52	7（13.46）	45（86.54）	5（9.62）	47（90.38）
χ² 值	-	46.664		44.164
P值	-	0.000		0.000

资料	预后不良组（n = 47）	预后良好组（n = 109）	χ ² 值	P值
性别
男	35（74.47）	73（66.97）	0.866	0.352
女	12（25.53）	36（33.03）	0.866	0.352
年龄
≤ 40岁	30（63.83）	93（85.32）	9.094	0.003
> 40岁	17（36.17）	16（14.68）	9.094	0.003
术前KPS
> 70分	28（59.57）	96（88.07）	16.358	< 0.001
≤ 70分	19（40.43）	13（11.93）	16.358	< 0.001
术前水肿
是	44（93.62）	95（87.16）	1.412	0.235
否	3（6.38）	14（12.84）	1.412	0.235
术前癫痫
是	17（36.17）	29（26.61）	1.445	0.229
否	30（63.83）	80（73.39）	1.445	0.229
肿瘤最大直径
≥ 6 cm	25（53.19）	21（19.27）	18.178	< 0.001
< 6 cm	22（46.81）	88（80.73）	18.178	< 0.001
肿瘤病理分级
Ⅰ-Ⅱ级	15（31.91）	76（69.72）	19.315	< 0.001
Ⅲ-Ⅳ级	32（68.09）	33（30.28）	19.315	< 0.001
手术术式
全切除术	20（42.55）	69（63.30）	5.770	0.016
次全切术	27（57.45）	40（36.70）	5.770	0.016
术后放疗
是	21（44.68）	78（71.56）	10.232	0.001
否	26（55.32）	31（28.44）	10.232	0.001
术后化疗
是	39（82.98）	102（93.58）	4.245	0.039
否	8（17.02）	7（6.42）	4.245	0.039
替莫唑胺疗程
≥ 4个疗程	27（57.45）	87（79.82）	8.352	0.004
< 4个疗程	20（42.55）	22（20.18）	8.352	0.004
ZEB2表达
阳性	42（89.36）	64（58.72）	14.162	< 0.001
阴性	5（10.64）	45（41.28）	14.162	< 0.001
CCL20表达
阳性	41（87.23）	57（52.29）	17.165	< 0.001
阴性	6（12.77）	52（47.71）	17.165	< 0.001

因素	赋值	因素	赋值
年龄	≤ 40岁 = 0，> 40岁 = 1	术前KPS	> 70分 = 0， ≤ 70分 = 1
肿瘤最大直径	< 6 cm = 0，≥ 6 cm = 1	肿瘤病理分级	Ⅰ?Ⅱ级 = 0，Ⅲ?Ⅳ级 = 1
手术术式	全切除术 = 0，次全切术 = 1	术后放疗	是 = 0，否 = 1
术后化疗	是 = 0，否 = 1	替莫唑胺疗程	≥ 4个 = 0，< 4个 = 1
ZEB2表达	阴性 = 0，阳性 = 1	CCL20表达	阴性 = 0，阳性 = 1
脑胶质瘤患者预后	良好 = 0，不良 = 1

影响因素	单因素分析				多因素分析
影响因素	SE	HR	95% CI	P值	SE	HR	95% CI	P值
年龄	0.548	3.367	1.150 ~ 9.856	0.027	0.545	3.382	1.162 ~ 9.842	0.025
术前KPS	0.237	0.534	0.336 ~ 0.850	0.008	0.244	0.530	0.329 ~ 0.855	0.009
肿瘤最大直径	0.632	6.495	1.882 ~ 22.415	0.003	0.642	6.451	1.833 ~ 22.704	0.004
肿瘤病理分级	0.589	7.882	2.485 ~ 25.004	0.000	0.594	7.818	2.440 ~ 25.045	0.001
手术术式	0.351	2.006	1.008 ~ 3.991	0.047	0.359	2.012	0.995 ~ 4.066	0.051
术后放疗	0.164	0.683	0.495 ~ 0.942	0.020	0.162	0.688	0.501 ~ 0.945	0.021
术后化疗	0.116	0.854	0.680 ~ 1.072	0.174	0.121	0.849	0.670 ~ 1.076	0.176
替莫唑胺疗程	0.139	0.751	0.572 ~ 0.986	0.039	0.137	0.757	0.579 ~ 0.990	0.042
ZEB2表达	0.652	5.239	1.460 ~ 18.804	0.011	0.657	5.232	1.444 ~ 18.963	0.012
CCL20表达	0.596	7.104	2.209 ~ 22.847	0.001	0.603	7.112	2.181 ~ 23.189	0.001

[1]	Xiaomei CHEN,Anqi WANG,Jizhen YANG,Miao YU. Prognosis and immune correlation analysis of m1A/m5C/m6A/m7G regulated genes in gastric cancer [J]. The Journal of Practical Medicine, 2024, 40(9): 1230-1237.
[2]	Futao DANG,Yingmei TANG,Haiyan FU,Huanlong LI,Jiamin XU,Xu. TAN. The efficacy of artificial （nonbiological） extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis [J]. The Journal of Practical Medicine, 2024, 40(7): 955-961.
[3]	Xiya MA,Hu JI,Zehua ZHU,Bo PAN,Qiang XIE,Xiaobo. YAO. The predictive value of ¹⁸F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy [J]. The Journal of Practical Medicine, 2024, 40(7): 966-971.
[4]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[5]	Sibo LONG,Yan CHEN,Xintong ZHANG,Yanjun YIN,Limei YANG,Maike ZHENG,Chaohong WANG,Qing SUN,Jun YAN,Yiheng SHI,Guangli SHI,Yan ZHAO,Guirong. WANG. Serum levels of procalcitonin， interleukin⁃6 and interleukin⁃8 in patients with COVID⁃19 infection at admission and their significance in patient prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 471-475.
[6]	Zixu SONG,Guangzheng ZHU,Chenxu GUO,Jiaqi WU,Ligong ZHANG,Jun. QIAN. Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis [J]. The Journal of Practical Medicine, 2024, 40(4): 496-502.
[7]	Yichen WANG,Yanwen YAN,Meihui SONG,Xiangjun XUE,Wenguang ZHOU,Yuquan LI,Ling QI,Guanghua LI,Xiangzong ZENG. Clinical significance of HOXB4 gene expression levels in myelodysplastic syndromes [J]. The Journal of Practical Medicine, 2024, 40(3): 321-325.
[8]	Jia CUI,Mingming ZHANG,Na WANG,Wei GAO,Fei LI. Correlation analysis of glucose and lipid metabolism indicators combined with antiphospholipid antibodies on prognosis of patients with atherosclerosis [J]. The Journal of Practical Medicine, 2024, 40(3): 326-329.
[9]	Shuang CHEN,Na YANG,Yudong HUANG,Xiangfeng KONG,Jintao LI,Yizhong TANG,Kexiong MA,Yangyang ZHANG,Yuandong ZHANG,Chengde REN. Relationship between serum miR-21 and miR-27b levels and prognosis of patients with renal clear cell carcinoma [J]. The Journal of Practical Medicine, 2024, 40(3): 343-348.
[10]	Jian ZHAO,Songjie LIU,Guanchao ZHANG,Yuhou SHEN,Fengchen LI,Bing XU. Expression of CENPF and miR⁃1⁃3p in the serum of patients with advanced gastric cancer and their correlation with prognosis [J]. The Journal of Practical Medicine, 2024, 40(3): 365-370.
[11]	Zhijie XIA,Jun LI,Qian GAO,Zhicheng LI,Zhongfang. XIA. Effect and prognosis of preauricular fistula treated by double⁃incision tunnel combined with preauricular tissue and cartilage resection [J]. The Journal of Practical Medicine, 2024, 40(22): 3179-3183.
[12]	Chengcai DAI,Zhenxing CHENG,Qianqian TU. The prognostic value of serum cystatin C combined with bedside renal ultrasound in patients with sepsis⁃induced acute kidney injury [J]. The Journal of Practical Medicine, 2024, 40(22): 3226-3231.
[13]	Kaiyang WANG,Jing TAO,Tingting WU,Jiahui YONG,Guoqing LI,Xiang XIE,Yining. YANG. Correlation of novel anthropometric indicators with long⁃term prognosis in patients with acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(21): 3040-3046.
[14]	Pixi WEI,Yu DENG,Cailing ZHAO,Liu XU,Min ZHANG. The expression of WDR5 in cervical cancer tissue and its relationship with clinical and pathological characteristics of patients [J]. The Journal of Practical Medicine, 2024, 40(2): 169-173.
[15]	Xueyan HU,Fanliang MENG,Juanjuan. DONG. Prognostic analysis of patients with bone metastases from primary non-small cell lung cancer with different pathologic staging [J]. The Journal of Practical Medicine, 2024, 40(16): 2316-2325.

Expression of ZEB2 and CCL20 in glioma tissue and their correlation with prognosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 25

Related Articles 15

Recommended Articles

Metrics

Comments